Published online by Cambridge University Press: 15 February 2011
Inhalation of dry powders comprised of large porous particles appears to promote long therapeutic action and increased systemic bioavailability (1-3). Relative to standard inhalation aerosols, dry powders possessing large porous particles clear relatively slowly from the lungs once inhaled (1) and show less aggregation prior to delivery. The diminished aggregation properties of large porous particles permits their use in a simple (and inexpensive) device without the need for carrier particles.